Rising Tide Foundation
23
14
19
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
4.3%
1 terminated/withdrawn out of 23 trials
75.0%
-11.5% vs industry average
4%
1 trials in Phase 3/4
167%
5 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Role: collaborator
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Role: collaborator
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
Role: collaborator
Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance
Role: collaborator
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
Role: collaborator
Neuroblastoma Precision Trial
Role: collaborator
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
Role: collaborator
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS
Role: collaborator
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
Role: collaborator
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
Role: collaborator
Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy
Role: collaborator
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
Role: collaborator
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
Role: collaborator
TOward a comPrehensive Supportive Care Intervention for Older Men With Metastatic Prostate Cancer
Role: collaborator
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
Role: collaborator
Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas
Role: collaborator
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma
Role: collaborator
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
Role: collaborator
ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
Role: collaborator
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
Role: collaborator